"Armed with new insights into how metastatic prostate tumors gain resistance to the next-generation androgen inhibitor abiraterone, Cleveland Clinic oncologist Nima Sharifi, MD, has discovered a way to make the drug’s activity more durable and potent.
Pairing abiraterone (abi) with the enzyme inhibitor dutasteride modifies abi’s metabolic conversion, blocking production of a tumor-promoting metabolite while aiding accumulation of another metabolite with strong anti-tumor effects, Dr. Sharifi and colleagues report in Nature. The study builds on his extensive previous research into prostate oncogenesis.
“These findings hold enormous potential for changing the way abiraterone is prescribed to patients,” says Dr. Sharifi who holds the Kendrick Family Endowed Chair for Prostate Cancer Research and is the study’s senior author. “While more work is needed to determine the ultimate clinical effect of biochemically altering abiraterone metabolism in this way, our team has identified a promising new combination therapy that stands to improve the care of men with metastatic castration-resistant prostate cancer.”
🤖 ChatGPT on Cancer-Fighting Exercise💪 vs PCa
Abiraterone + Prednisone with Preexisting CAD
